Simply Wall St
4 min read
The Australian market is experiencing a challenging period, with futures indicating a significant downturn and volatility on the rise. Despite these turbulent conditions, penny stocks—though an old-fashioned term—remain an intriguing area for investors seeking value in smaller or newer companies. By focusing on those with strong financial foundations, such stocks can offer potential stability and growth opportunities. In this article, we explore three penny stocks that exhibit financial strength and may present promising prospects for investors looking to uncover hidden value.
|
Name |
Share Price |
Market Cap |
Financial Health Rating |
|
Dusk Group (ASX:DSK) |
A$0.82 |
A$51.06M |
★★★★★★ |
|
IVE Group (ASX:IGL) |
A$2.96 |
A$454.92M |
★★★★★☆ |
|
MotorCycle Holdings (ASX:MTO) |
A$3.60 |
A$265.7M |
★★★★★★ |
|
Veris (ASX:VRS) |
A$0.066 |
A$34.76M |
★★★★★★ |
|
West African Resources (ASX:WAF) |
A$3.04 |
A$3.47B |
★★★★★★ |
|
Praemium (ASX:PPS) |
A$0.79 |
A$377.96M |
★★★★★★ |
|
Service Stream (ASX:SSM) |
A$2.11 |
A$1.29B |
★★★★★★ |
|
Fleetwood (ASX:FWD) |
A$2.68 |
A$248.12M |
★★★★★★ |
|
MaxiPARTS (ASX:MXI) |
A$2.39 |
A$132.75M |
★★★★★★ |
|
GWA Group (ASX:GWA) |
A$2.38 |
A$624.51M |
★★★★★☆ |
Click here to see the full list of 414 stocks from our ASX Penny Stocks screener.
We’re going to check out a few of the best picks from our screener tool.
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Atturra Limited, along with its subsidiaries, offers advisory and information technology solutions across Australia, New Zealand, Singapore, North America, and Hong Kong with a market cap of A$277.97 million.
Operations: The company generates revenue of A$300.62 million from its Information Technology (IT) Solutions segment.
Market Cap: A$277.97M
Atturra Limited, with a market cap of A$277.97 million and revenue of A$300.62 million, shows financial stability through its well-covered interest payments and operating cash flow relative to debt. The company has more cash than total debt, indicating sound liquidity management. Despite stable weekly volatility and experienced leadership, Atturra faces challenges with low return on equity at 4% and declining net profit margins from 4% to 3%. Recent share buybacks demonstrate shareholder value focus, while earnings are forecasted to grow by nearly 17% annually despite past negative growth trends compared to industry averages.
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Cleo Diagnostics Ltd is a biotechnology company that develops and commercializes non-invasive blood tests for detecting ovarian cancer in Australia, with a market cap of A$82.88 million.
